Publications Etudes et Recherche en Economie de la Santé 2024-25
- PFMG2025 contributors. PFMG2025-integrating genomic medicine into the national healthcare system in France. Lancet Reg Health Eur 2025
- Fraslin AM, Stockholm T, Filleron T, Bertaut A, Blanc-Lapierre A, Marghadi J, Aupérin A, Bonastre J.
A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality. Journal of Clinical Epidemiology 2025 - Fraslin AM, Benhamou S, Lebret T, Radvanyi F, Allory Y, Karimi M, Bonastre J. Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database. Clinical Genitourinary Cancer 2025
- Negrier S, Bonastre J, Colrat F, Teitsson S, Knight C, Ni L, Chevalier J, Branchoux S, Rouprêt M.
Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France. World Journal of Urology 2025 - Fraslin A, Colrat F, Karimi M, Bonastre J, Groussard K, Teitsson S, Prudent A, Branchoux S, Radvanyi F, Benhamou S, Allory Y, Lebret T. Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort. BMC Urology 2025
- Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L; TPExtreme-ECO Group; Bourhis J, Guigay J, Bonastre J. Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Value in Health 2025
- Leleu H, Berkovitch Q, Bonastre J, Caramella C, Giroux-Leprieur É, Lefèvre L, Lavaud P, Todea A, Wislez M, Hofman P. Efficacy and cost-effec²tiveness of lung cancer screening in France with low-dose computed tomography. European journal of cancer prevention 2025
- Lefèvre G, Borget I, Lefèvre C, Maherzi C, Nucit A, Hennaoui M, Schmidt A, Lennon H, Grenier B, Daydé F, Mahlaoui N. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PloS One 2025
- Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M. Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland. Journal of Medical Economics 2025
- Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, D'hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecologic and Obstetric Investigation 2025
- Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway? Therapie 2025
- Costa N, Gombault E, Marcélo C, Pagès A, Molinier L, de Souto Barreto P, Rolland Y. Association between intrinsic capacities limitations and annual healthcare costs in Nursing Home residents. BMC Geriatrics 2025
- Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A. Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access. Future Oncology
2025 - Lueza B, Aupérin A, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, Bonastre J. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma. Eur J Health Econ. 2024
- Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, Foulon S, Besse B. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur 2024
- Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024
- Bayle A, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R, Bonastre J. Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al. Ann Oncol. 2024
- Bayle A, Marino P, Baffert S, Margier J, Bonastre J. Coût des technologies de séquençage haut débit (NGS) : revue de la littérature et enseignements [Cost of high-throughput sequencing (NGS) technologies: Literature review and insights]. Bull Cancer. 2024
- Farah L, Borget I, Martelli N, Vallee A. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. J Med Internet Res. 2024
- Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs. BioDrugs. 2024
- Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, D'hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecol Obstet Invest. 2024
- Grumberg V, Cotté FE, Giroux-Leprieur E, Gaudin AF, Lebbé C, Borget I. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. ESMO Open. 2024
- Cartron G, Thieblemont C, Borget I, Rioufol C, Berthet M, Portal C, Baujat C, Alaoui E, Baffert S, Lacroix D, Bories P, Yakoub-Agha I, Houot R. Évaluation en vie réelle du parcours de soins des patients éligibles à un traitement par axicabtagene ciloleucel : cohorte multicentrique IMPA-CT. Bull Cancer 2024
- Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, Malapelle U, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. Crit Rev Oncol Hematol 2024
Publications Etudes et Recherche en Economie de la Santé 2014-23
► Liste des publications Etudes et Recherche en Economie de la Santé 2014-2023 (document PDF)
Catégorie de la page:
